Carasent: On Track Towards the Financial Targets - Redeye

Redeye retains its positive view of Carasent following the Q3 report. We believe the strong CARR and further growth prospects – boosted by the new surgical module, for example – and a limited need for increased OPEX set Carasent for solid organic growth and expanding margins over the next few years.

Länk till analysen i sin helhet: https://www.redeye.se/research/1048055/carasent-on-track-towards-the-financial-targets?utm_source=finwire&utm_medium=RSS